Innovations In Clinical Neuroscience

SEP-OCT 2014

A peer-reviewed, evidence-based journal for clinicians in the field of neuroscience

Issue link: http://innovationscns.epubxp.com/i/425963

Contents of this Issue

Navigation

Page 180 of 201

[ V O L U M E 1 1 , N U M B E R 9 – 1 0 , S E P T E M B E R – O C T O B E R 2 0 1 4 ] Innovations in CLINICAL NEUROSCIENCE 181 suicidality is a much stronger reflection of global suicidality severity than the count of events. The clinical value of this finding is t hat clinicians may get a better reflection of the global severity of suicidality by asking the questions, "How much time do you usually spend per day with any suicidal impulses, thoughts, or actions?" and "Were there some days when you spent more than this amount of time?" The research application of this finding is that time spent may be a useful outcome measure in studies investigating treatment-emergent suicidality and in detecting the treatment effects of future anti- suicidal medications. These questions are included in the S-STS. Further investigation of this concept with larger samples and in different settings is needed before we can state that this finding is generalizable, reliable, and useful. Limitations. The use of only one s ubject for this case study means these findings may not be generalizable to other cases of suicidality. The subject tracked the global severity of her suicidality prior to tracking any other daily data. This differs from the custom of rating global severity of a condition after rating the detailed phenomena of the condition, and this may have impacted the results. CONCLUSION This case study suggests that tracking the time a patient spends experiencing suicidality may be more clinically useful and may have more value than tracking the count of events of suicidality in assessing global severity of suicidality. REFERENCES 1. United States Food and Drug Administration, United States Department of Health and Human Services. Guidance for Industry: Suicidality: Prospective Assessment of Occurrence in Clinical Trials, Draft Guidance. August 2012. Revision 1. http://www.fda.gov/downloads/Dru gs/Guidances/UCM225130.pdf. Accessed October 1, 2014. 2. Sheehan DV, Giddens JG, Sheehan IS. Status update of the Sheehan- Suicidality Tracking Scale (S-STS) 2014. Innov Clin Neurosci. 2014;11(9–10):93–140.

Articles in this issue

Links on this page

Archives of this issue

view archives of Innovations In Clinical Neuroscience - SEP-OCT 2014